August 6, 2019
Daiichi Sankyo’s Takashi Ikegami (left), Ikunori Takahashi Speak to Jiho in Interview on Aug. 1 Daiichi Sankyo is ratcheting up its promotional activities for its FLT3 inhibitor Vanflyta (quizartinib), its first in-house developed oncology drug that snagged Japan approval in...read more